Q4-FY26 · Anand Desai
Our performance during the year was a result of strong execution across key business verticals, increasing contribution from high value chemistries and scale up of commercial molecules.
Anupam Rasayan India · tone and specificity signals across the available quarters.
Language signals
Our performance during the year was a result of strong execution across key business verticals, increasing contribution from high value chemistries and scale up of commercial molecules.
If I look at the proforma basis business across the four companies, Anupam should be today around about ₹1,676 crores standalone, Tanfac ₹711, JHawk roughly ₹722, and Bliss ₹927, so total we should be looking at over ₹4,000 crores revenue and an EBITDA of around about ₹834 crores.
We believe that the growth trajectory here in standalone business continues to grow across all the three verticals and then JHawk and then Bliss all three put together should be able to give a further fillip to the company's performance.